WO2008111464A1 - スプライシング異常を指標とする抗ガン剤の作用検定方法 - Google Patents

スプライシング異常を指標とする抗ガン剤の作用検定方法 Download PDF

Info

Publication number
WO2008111464A1
WO2008111464A1 PCT/JP2008/053977 JP2008053977W WO2008111464A1 WO 2008111464 A1 WO2008111464 A1 WO 2008111464A1 JP 2008053977 W JP2008053977 W JP 2008053977W WO 2008111464 A1 WO2008111464 A1 WO 2008111464A1
Authority
WO
WIPO (PCT)
Prior art keywords
examination
action
measure
cancer agent
splicing defect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053977
Other languages
English (en)
French (fr)
Inventor
Yoshiharu Mizui
Naoko Hata
Masao Iwata
Koji Sagane
Mai Uesugi
Tadashi Kadowaki
Taku Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to EP08721397A priority Critical patent/EP2136209A4/en
Priority to JP2009503997A priority patent/JPWO2008111464A1/ja
Priority to US12/529,959 priority patent/US20100021918A1/en
Publication of WO2008111464A1 publication Critical patent/WO2008111464A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　本発明は、プラジエノライド誘導体の生体への作用を検定するための方法、プローブ、プライマー、抗体、試薬、およびキットの提供をその目的とする。本発明によれば、スプライシング異常を指標とする、プラジエノライド誘導体の作用検定方法が提供される。
PCT/JP2008/053977 2007-03-05 2008-03-05 スプライシング異常を指標とする抗ガン剤の作用検定方法 Ceased WO2008111464A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08721397A EP2136209A4 (en) 2007-03-05 2008-03-05 METHOD FOR EXAMINING AN ACTION OF AN ANTI-CANCER AGENT USING A SPLICE DEFECT AS A MEASUREMENT
JP2009503997A JPWO2008111464A1 (ja) 2007-03-05 2008-03-05 スプライシング異常を指標とする抗ガン剤の作用検定方法
US12/529,959 US20100021918A1 (en) 2007-03-05 2008-03-05 Method for assaying action of antitumor agent using splicing defects as index

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90477407P 2007-03-05 2007-03-05
US60/904,774 2007-03-05
US96040307P 2007-09-28 2007-09-28
US60/960,403 2007-09-28

Publications (1)

Publication Number Publication Date
WO2008111464A1 true WO2008111464A1 (ja) 2008-09-18

Family

ID=39759407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053977 Ceased WO2008111464A1 (ja) 2007-03-05 2008-03-05 スプライシング異常を指標とする抗ガン剤の作用検定方法

Country Status (4)

Country Link
US (1) US20100021918A1 (ja)
EP (1) EP2136209A4 (ja)
JP (1) JPWO2008111464A1 (ja)
WO (1) WO2008111464A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111897A1 (ja) * 2012-01-27 2013-08-01 国立大学法人大阪大学 新規抗腫瘍剤及びそのスクリーニング方法
JP6067943B1 (ja) * 2014-05-15 2017-01-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドピリジン化合物及び使用の方法
JP2018502831A (ja) * 2015-11-18 2018-02-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体形態のプラジエノライドピリジン化合物及び使用の方法
JP2021521176A (ja) * 2018-04-12 2021-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
CN115429902A (zh) * 2021-06-04 2022-12-06 中南大学 磁性氧化铁细胞标记材料及其制备和应用
CN116217737A (zh) * 2020-07-29 2023-06-06 浙江海隆生物科技有限公司 非洲猪瘟病毒免疫原的p49突变融合蛋白、重组载体、工程菌及制备方法和应用
CN117925840A (zh) * 2024-01-30 2024-04-26 中国医学科学院基础医学研究所 Slfn11在cgt-odn治疗癌症疗效预测中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6876680B2 (ja) 2015-09-01 2021-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CN111549113B (zh) * 2020-04-17 2022-10-14 中山大学 一种类风湿性关节炎诊断标记物及其应用
JP7573898B2 (ja) * 2020-10-27 2024-10-28 デイツ・バイオ・カンパニー・リミテッド 腫瘍ターゲティングの向上及びウイルスの大量産生が可能な間葉系幹細胞
CN112870363B (zh) * 2021-04-03 2022-02-18 兰州大学第一医院 人pcid2蛋白在制备或筛选抗肿瘤药物中的应用及具有抗肿瘤活性的化合物
CN113416713A (zh) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种重组腺病毒的构建及其应用
CN113588954B (zh) * 2021-07-29 2023-04-21 福州大学 血清cyr61-sno蛋白作为标志物在制备新型乳腺癌快速检测试剂盒中的应用
CN114875037B (zh) * 2022-05-31 2023-06-06 河南农业大学 鸡gbp4l基因、表达载体及应用
CN115814060A (zh) * 2022-08-30 2023-03-21 长春科技学院 胸腺素β10在制备修复肝损伤药物中的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500684A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性アミノ酸連鎖の決定方法
WO2000028082A1 (fr) 1998-11-09 2000-05-18 Eiken Kagaku Kabushiki Kaisha Procede de synthese d'acide nucleique
WO2002060890A1 (en) 2001-02-01 2002-08-08 Mercian Corporation Novel physiologically active substances
JP2002223760A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd オリゴヌクレオチドアレイ及びスプライシングの検出方法
WO2003099813A1 (en) 2002-05-29 2003-12-04 Mercian Corporation Novel physiolgically active substances
JP2004208650A (ja) * 2003-01-08 2004-07-29 Hitachi High-Technologies Corp 核酸塩基配列決定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075681A1 (ja) * 2004-02-06 2005-08-18 Eisai R & D Management Co., Ltd. 抗癌剤に対する癌細胞の感受性を検定する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500684A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性アミノ酸連鎖の決定方法
WO2000028082A1 (fr) 1998-11-09 2000-05-18 Eiken Kagaku Kabushiki Kaisha Procede de synthese d'acide nucleique
JP2002223760A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd オリゴヌクレオチドアレイ及びスプライシングの検出方法
WO2002060890A1 (en) 2001-02-01 2002-08-08 Mercian Corporation Novel physiologically active substances
WO2003099813A1 (en) 2002-05-29 2003-12-04 Mercian Corporation Novel physiolgically active substances
JP2004208650A (ja) * 2003-01-08 2004-07-29 Hitachi High-Technologies Corp 核酸塩基配列決定方法

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS
"Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR PRESS
ANAL.BIOCHEM., vol. 151, 1985, pages 540 - 6
CAMPA, M.J. ET AL., CANCER RES., vol. 63, 2003, pages 1652 - 1656
CHOU-FASMAN, ANN.REV.BIOCHEM., vol. 47, 1978, pages 251 - 76
DALBADIE-MCFARLAND ET AL., PROC.NATL.ACAD.SCI. USA, vol. 79, 1982, pages 6409 - 13
HASHIMOTO-GOTO ET AL., GENE, vol. 152, 1995, pages 271 - 5
KINKEL, PROC.NATL.ACAD.SCI.USA, vol. 82, 1985, pages 488 - 92
KRAMER; FRITZ, METHOD.ENZYMOL., vol. 154, 1987, pages 350 - 67
KUNKEL, METHOD. ENZYMOL., vol. 85, 1988, pages 2763 - 6
KYTE-DOOLITTLE, J.MOLBIOL., vol. 157, 1982, pages 105 - 22
MARK ET AL., PROC.NATL.ACAD.SCI.USA, vol. 81, 1984, pages 5662 - 6
METH. ENZYM., vol. 164, 1988, pages 765
MIZUI ET AL., J. ANTIBIOTICS, vol. 577, 2004, pages 188 - 196
NATURE, vol. 256, 1975, pages 495
SAKAI T.: "Biseibutsu Shigen kara no Shinki Koshuyo Kassei Busshitsu no Tansaku", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, no. SUPPL. 5, 2006, pages 32 - 33, XP001538827 *
See also references of EP2136209A4
WANG ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3
ZOLLER; SMITH, NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111897A1 (ja) * 2012-01-27 2013-08-01 国立大学法人大阪大学 新規抗腫瘍剤及びそのスクリーニング方法
JPWO2013111897A1 (ja) * 2012-01-27 2015-05-11 国立大学法人大阪大学 新規抗腫瘍剤及びそのスクリーニング方法
JP6067943B1 (ja) * 2014-05-15 2017-01-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドピリジン化合物及び使用の方法
JP2018502831A (ja) * 2015-11-18 2018-02-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体形態のプラジエノライドピリジン化合物及び使用の方法
JP2018111715A (ja) * 2015-11-18 2018-07-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体形態のプラジエノライドピリジン化合物及び使用の方法
JP7334181B2 (ja) 2018-04-12 2023-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP2021521176A (ja) * 2018-04-12 2021-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP2023175691A (ja) * 2018-04-12 2023-12-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP7676484B2 (ja) 2018-04-12 2025-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
CN116217737A (zh) * 2020-07-29 2023-06-06 浙江海隆生物科技有限公司 非洲猪瘟病毒免疫原的p49突变融合蛋白、重组载体、工程菌及制备方法和应用
CN115429902A (zh) * 2021-06-04 2022-12-06 中南大学 磁性氧化铁细胞标记材料及其制备和应用
CN115429902B (zh) * 2021-06-04 2023-08-18 中南大学 磁性氧化铁细胞标记材料及其制备和应用
CN117925840A (zh) * 2024-01-30 2024-04-26 中国医学科学院基础医学研究所 Slfn11在cgt-odn治疗癌症疗效预测中的应用

Also Published As

Publication number Publication date
EP2136209A1 (en) 2009-12-23
EP2136209A4 (en) 2010-10-27
JPWO2008111464A1 (ja) 2010-06-24
US20100021918A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
WO2009129505A3 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2010041892A3 (ko) Aimp1 폴리펩티드의 신규한 용도
WO2010090471A3 (ko) 제1형 당뇨병의 신규한 진단 마커
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
PL3026874T3 (pl) Składnik do badania płynu ustrojowego do detekcji analitu
WO2010039809A3 (en) Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples
WO2012021407A3 (en) Biomarkers for stroke
WO2007087261A3 (en) Rapid test apparatus
WO2007140185A3 (en) Methods for non-invasive analyte measurement
EP2455758B8 (en) METHOD FOR MEASUREMENT OF Mac-2-binding protein, METHOD FOR DETECTION OF HEPATIC DISEASES by measuring Mac-2-binding protein, REAGENT FOR QUANTIFICATION OF Mac-2-binding protein
EP1972269B8 (de) System zur in-vivo Messung einer Analytkonzentration
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
WO2007136980A3 (en) Diagnostic test media and methods for the manufacture thereof
WO2010065781A3 (en) Lateral flow strip assay with immobilized conjugate
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2008027098A3 (en) Biosensor for measurement of species in a body fluid
WO2010051544A3 (en) Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
WO2007092552A3 (en) Device and methods for detecting and quantifying one or more target agents
WO2007149809A3 (en) Tacrolimus standard and methods of using same
WO2012032345A3 (en) Biomarker signatures and uses thereof
WO2011074802A3 (ko) 전립선암 진단용 키트 및 진단방법
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721397

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009503997

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12529959

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008721397

Country of ref document: EP